The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
Alessia Casolaro(Nerviano Medical Sciences), Rachele Alzani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Josée Golay(Azienda Ospedaliero Universitaria Ospedali Riuniti), Silvia Bungaro(University of Milano-Bicocca), Martino Introna(Mario Negri Institute for Pharmacological Research), Francesco Marchesi(Nerviano Medical Sciences), Marco Losa(Vita-Salute San Raffaele University), Alice Pezzoni(Fondazione Humanitas per la Ricerca), Gemma Texidó(Nerviano Medical Sciences), Clara Albanese(University of L'Aquila), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Barbara Valsasina(Nerviano Medical Sciences), Veronica Patton(University of L'Aquila), Giovanni Cazzaniga(University of Milano-Bicocca), Enrico Pesenti, Sabrina Cribioli(Nerviano Medical Sciences), Roberta Ceruti(Nerviano Medical Sciences), Ursula Giussani
Cited by 34
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627